A Study of Armodafinil for Patients with Dementia with Lewy Bodies

Overview

About this study

The purpose of this study is to examine the effects of the medication Armodafinil in patients who have dementia with Lewy bodies which is associated with memory loss and other thinking problems, excessive daytime sleepiness, hallucinations, delusions, apathy, and reduced quality of life.

 

 

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria

  • Diagnosis of clinically possible or probable DLB using established criteria
  • Age 50-90 inclusive
  • Epworth Sleepiness Scale score of 8 or greater
  • MMSE score between 10 and 26 inclusive
  • No active medical disorder that could preclude participation in a drug treatment trial over a 12 week protocol
  • Stable medication regimen over previous four weeks
  • Absence of psychotropic medications at doses viewed by the clinician to be significantly impacting the patient's alertness during wakefulness
  • Absence of clinically significant primary sleep-related breathing disorder causing sleepiness as demonstrated by polysomnography (PSG) [ie, no significant upper airway resistance syndrome (UARS), obstructive sleep apnea (OSA), nor central sleep apnea (CSA) as reflected by a combined respiratory disturbance index (RDI) <15] OR adequate documentation of efficacy of treatment for UARS, OSA, and CSA
  • Caregiver that is with the patient at least 4 hours/day for at least 5 days per week
  • Patient and caregiver willing and able to participate in all study-related procedures
  • Capable of giving informed consent, or if appropriate, has caregiver capable of giving consent on the subject's behalf

Exclusion Criteria

  • Does not fulfill criteria for clinically possible or probable DLB
  • Age <50 or >90
  • Women with intact uterus and not post-menopausal unless pregnancy test performed at screening is negative
  • Epworth Sleepiness Scale score less than 8
  • MMSE score <10 or >26
  • Active medical disorder that could preclude participation in a drug treatment trial over a 52 week protocol, such as
    • Hypertension with BP readings exceeding 150 mm Hg systolic and 90 mm Hg diastolic
    • Hypersensitivity to modafinil, armodafinil, or any other conventional stimulants
    • Myocardial infarction or cerebral infarct over preceding year, stable or unstable angina, known symptomatic coronary artery disease
    • History of left ventricular hypertrophy or mitral valve prolapse
    • History of chronic or paroxysmal atrial fibrillation, chronic or paroxysmal atrial flutter, ventricular fibrillation, or ventricular tachycardia
    • History of cancer over preceding 1 year (excluding squamous or basal cell carcinoma of the skin)
    • History of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS)
    • Pulmonary disease requiring oral or inhalatory medications
    • Any other medical disorder considered by the study physicians as inappropriate for any wake-promoting medication
  • Medication regimen has not been stable over preceding four weeks
  • Concurrent use of lamotrigine or oxcarbazepine
  • Presence of over-the-counter and prescription psychotropic medications at doses viewed by the clinician to be significantly impacting the patient's alertness during wakefulness, such as
    • Clonazepam > 1 mg/night
    • Seroquel > 100 mg/night
    • Zyprexa > 10 mg/night
  • Presence of another clinically-significant primary sleep disorder (eg, UARS, OSA, CSA) that is not being treated
  • Clinically significant abnormalities on screening ECG or laboratory tests
  • Patient or caregiver unwilling or unable to participate in all study-related procedures
  • Caregiver is not with patient at least 4 hours/day for at least 5 days/week
  • Patient or caregiver unwilling or unable to provide informed consent
  • CT or MRI evidence of a clinically significant structural lesion that could account for the participants dementia

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Bradley Boeve, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20312907

Mayo Clinic Footer